'You're spot on malmanu. BSI will await results of FDA initial 20 patient safety assessment before even reconsidering CE approval'
You may be right, or not.
If so then it will be a long wait.
As OSL are so keen to try and draw a comparison with SRX, lets look at the current phase 1 for kidney treatment from SRX. With a product that had a PMA in 2002, and with many thousands of treatments, a new indication for Kidney has taken over 2 years to recruit 24 pts. Maybe SRX are just incompetent.
OSL Price at posting:
13.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)